Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Current Assets: 2010-2024

Historic Current Assets for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $54.0 million.

  • OptimizeRx's Current Assets rose 2006.99% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.1 million, marking a year-over-year increase of 1049.57%. This contributed to the annual value of $54.0 million for FY2024, which is 66.26% down from last year.
  • As of FY2024, OptimizeRx's Current Assets stood at $54.0 million, which was down 66.26% from $54.3 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Current Assets registered a high of $115.1 million during FY2021, and its lowest value of $32.9 million during FY2020.
  • Its 5-year average for Current Assets is $71.0 million, with a median of $54.3 million in 2023.
  • As far as peak fluctuations go, OptimizeRx's Current Assets skyrocketed by 25032.32% in 2021, and later plummeted by 4488.45% in 2023.
  • Over the past 5 years, OptimizeRx's Current Assets (Annual) stood at $32.9 million in 2020, then skyrocketed by 250.32% to $115.1 million in 2021, then dropped by 14.37% to $98.6 million in 2022, then plummeted by 44.88% to $54.3 million in 2023, then fell by 0.66% to $54.0 million in 2024.
  • Its last three reported values are $54.0 million in FY2024, $54.3 million for FY2023, and $98.6 million during FY2022.